Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer
In this phase II trial, we will evaluate the weekly schedule of topotecan in the second-line treatment of patients with small cell lung cancer
Lung Cancer
DRUG: Topotecan
Overall response rate
Median survival|1-year survival|Symptomatic improvement
Upon determination of eligibility, all patients will be receive:

* Topotecan